Wernicke J F, Sweet P M, van den Noort S, Mayberg H S, Armentrout S A
J Clin Lab Immunol. 1983 Dec;12(4):187-95.
A humoral factor having many of the physical properties of a glycoprotein and lacking many of the characteristics of other immunosuppressants has been detected in the serum and plasma of patients with active multiple sclerosis. Kinetic studies indicate that the earliest biochemical event inhibited by LTIF is the incorporation of labeled nucleotides into acid insoluble ribonucleic acid. This material, designated lymphocyte transformation inhibition factor (LTIF), inhibits blast transformation in mitogen-stimulated T lymphocytes. The serum factor is usually associated with active multiple sclerosis but is also detected in some lymphoproliferative disorders. Partial purification has separated this material from serum immunoglobulins, but these procedures led to an accelerated loss of biological activity.
在活动期多发性硬化症患者的血清和血浆中检测到一种体液因子，它具有许多糖蛋白的物理特性，且缺乏其他免疫抑制剂的许多特征。动力学研究表明，淋巴细胞转化抑制因子（LTIF）抑制的最早生化事件是将标记的核苷酸掺入酸不溶性核糖核酸中。这种物质，即淋巴细胞转化抑制因子（LTIF），可抑制有丝分裂原刺激的T淋巴细胞中的母细胞转化。血清因子通常与活动期多发性硬化症相关，但在一些淋巴增殖性疾病中也可检测到。部分纯化已将这种物质与血清免疫球蛋白分离，但这些操作导致生物活性加速丧失。
